Explore 3 Stock Ideas & Industry Insights Download Free Report

Tetratherix Ltd

Company price
6.4 AUD 0.05 ( 0.79%)
Last update at 2026-11-12T04:59:00Z
VOLUME
45105
Market Cap
310.70M

Momentum Score

…

Tetratherix Limited engages in biomaterial and regenerative medicine business in Australia and internationally. The company manufactures and commercialize medical devices in the areas of bone regeneration, tissue spacing, tissue regeneration, and precision medicine applications through its Tetramatrix platform technology. Tetratherix Limited was incorporated in 2015 and is based in Alexandria, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
6.39
Low
6.96
High
52 Week Price Range
3.09
Low
8.08
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Tetratherix Ltd (ASX: TTX) is limited; the company appears to be an early-stage life sciences firm focused on developing biomedical technology and related intellectual property. Long-term growth could be driven by successful clinical or product development milestones, regulatory approvals, and licensing or commercial partnerships, and investors may find the stock attractive for exposure to early-stage biotech upside if execution proceeds as planned.

Primary investment risks include significant execution and financing risk typical of early-stage biotechs, including clinical or regulatory setbacks, high cash burn and potential dilution, and low share liquidity.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
6.35
Dividend Yield
-
Revenue TTM
3.86M
Revenue Per Share
0.08
Gross Profit TTM
3.86M
Debt / Equity
-
ROE
-31.08%
Net Debt
-
ROCE
-27.97%
Diluted EPS TTM
-0.18

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30
Type yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30
Income before tax -9.32M -9.43M -2.55M -1.82M
Net income -9.32M -9.43M -2.55M -1.82M
Selling general administrative 10.02M 1.01M 1.17M 0.86M
Gross profit 0.92M -1.97M -0.49M -0.58M
Reconciled depreciation 0.93M - - -
Operating income -12.50M -9.34M -2.43M -1.68M
Interest expense 0.10M - - -
Tax provision 0.00M 0.00M 0.00M 0.00M
Interest income 0.80M 0.08M 0.12M 0.14M
Net interest income 0.23M - - -
Total revenue 0.92M 1.14M 0.86M 0.57M
Total operating expenses - 10.49M 3.30M 2.25M
Cost of revenue - 3.11M 1.35M 1.15M
Total other income expense net 2.94M - - -
Net income from continuing ops -9.32M - - -
Net income applicable to common shares - -9.43M -2.55M -1.82M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30
Type yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30
Total assets 53.17M 31.83M 1.41M 1.40M
Intangible assets 1.16M 0.04M 0.02M -
Other current assets - 1.39M 0.01M 0.10M
Total liab 20.44M 4.59M 8.18M 5.95M
Total stockholder equity 32.73M 27.25M -6.78M -4.56M
Other current liab 5.47M - - -
Common stock - 47.20M 2.61M 1.89M
Capital stock 61.34M - - -
Retained earnings -29.28M -19.96M -9.39M -6.44M
Cash 34.36M 29.34M 0.13M 0.26M
Total current liabilities 8.48M 2.53M 6.14M 3.99M
Short term debt - 0.00M 0.00M 0.00M
Short long term debt 0.00M - - -
Property plant equipment - 0.89M 0.41M 0.47M
Total current assets 38.15M 30.91M 0.98M 0.93M
Long term investments 0.82M - - -
Long term debt 1.90M 1.83M 1.77M 1.69M
Inventory 0.25M - - -
Non currrent assets other 0.12M - - -
Non current assets total 15.02M - - -
Capital lease obligations 9.06M - - -
Long term debt total - 1.99M 1.99M 1.93M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30
Type yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30
Investments -0.82M - - -
Total cashflows from investing activities - -0.59M -0.04M -0.00M
Total cash from financing activities 13.62M 32.47M 2.42M 0.65M
Net income -9.32M - - -
Change in cash 4.87M 29.21M -0.13M 0.25M
Begin period cash flow 29.34M - - -
End period cash flow 34.36M - - -
Total cash from operating activities - -2.67M -2.56M -0.39M
Issuance of capital stock 13.62M - - -
Sale purchase of stock -0.36M 25.00M 2.91M 0.30M
Other cashflows from financing activities - -3.47M - -
Capital expenditures 5.55M 0.59M 0.04M 0.00M
Change in working capital - 0.92M -2.48M 0.83M
Free cash flow -7.93M - - -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
TTX
Tetratherix Ltd
0.05
0.79%
6.40 - - 80.46 9.01 295.56
CSL
CSL Ltd
2.86
1.42%
204.54 - 22.57 6.15 4.48 4.82
TLX
TELIX Pharmaceuticals Ltd
-0.32
2.28%
13.70 93.87 166.67 5.37 6.37 3.85
NEU
Neuren Pharmaceuticals Ltd
-0.30
1.25%
23.66 154.93 36.36 42.38 7.52 31.95
MSB
Mesoblast Ltd
-0.07
3.69%
1.96 - 454.55 23.43 3.36 18.28

Profile*

Tetratherix Ltd

Tetratherix Limited engages in biomaterial and regenerative medicine business in Australia and internationally. The company manufactures and commercialize medical devices in the areas of bone regeneration, tissue spacing, tissue regeneration, and precision medicine applications through its Tetramatrix platform technology. Tetratherix Limited was incorporated in 2015 and is based in Alexandria, Australia.

Unit 29, Alexandria, NSW, Australia, 2015

25

Name Title Year Born
Mr. William Knox CEO & Executive Director NA
Dr. Ali Fathi Founder, CTO & Executive Director NA
Mr. Terence Abrams Founder & Chief Operating Officer NA
Ms. Cherie Beach Chief Financial Officer NA
Ms. Jane Miller Joint Company Secretary NA
Ms. Sally Greenwood Joint Company Secretary NA
Alex Washington Financial Controller NA
Mr. William Anthony Knox CEO, MD & Executive Director NA
Mr. Terence Abrams Founder & COO NA
Mr. Jacob Pfeffer General Counsel & Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…